CervoMed Inc. (CRVO)

15.50 -0.37 (-2.33%) At close: 04:00PM EDT

CervoMed Inc.

20 Park Plaza
Suite 424
Boston, MA 02116
United States
617 744 4400
https://www.cervomed.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. John J. Alam M.D.	Co-Founder, CEO, President & Director	680.25k	N/A	1962
Dr. Sylvie L. Gregoire Pharm.D.	Co-Founder & Director	352.43k	N/A	1961
Mr. William Robert Elder J.D.	CFO & General Counsel	407.55k	N/A	1983
Dr. Robert J. Cobuzzi Jr., Ph.D.	COO & Director	386.6k	N/A	1965
Ms. Kelly Blackburn M.H.A.	Senior Vice President of Clinical Development	404.94k	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Corporate governance

CervoMed Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.